Jobs
岗位职责:
- 作为技术转移活动的一部分,负责建立主要原材料质量标准、变更以及实施新原材料和消耗品的质量标准;
- 为复杂调查的故障排除和实验室系统的优化提供SME支持;
- 作为技术主题专家(SME),参与评估原材料和辅料的检测策略,并参与监管检查和客户稽查,以支持QC原材料活动;
- 优先考虑并专注于优化实验室系统和新技术,包括使用IT系统(例如Labware)和新仪器来实现原材料检测的现代化;
- 与QC分析开发、QC项目管理、生产、工艺科学和质量保证相关方进行跨职能合作,以实现公司目标;
- 与研究中心专家合作,领导风险评估并实施与原材料检测和质量标准相关的风险缓解策略;
- 准备并参与内部和外部审计,提供专业知识并确保所有综合方法符合全球监管标准;
- 与质量保证、生产和法规事务团队紧密合作,支持产品开发并确保无缝操作;
- 及时了解原材料测试技术的最新进展,并将相关创新融入现有流程;
- 根据ChP/USP/EP/JP指导原则支持方法开发和验证;
- 根据需要,撰写、审查并批准数据报告、超出质量标准(OOS)和趋势偏离(OOT)调查、偏差、CAPA和变更控制;
- 完成领导交办的其他任务。
任职要求:
- 学士学位,且在GMP环境中拥有8+年经验或 拥有GMP环境工作经验6+年以上的硕士学位或 博士,具有GMP环境4+年经验;
- 5+年分析检测经验,最好有原材料检测经验;
- 具有分析检测经验,最好是在生物制药行业进行的原材料检测;
- 对原材料试验(风险评估)的基于风险的方法有深入的了解 良好的英语听说读写能力;
- 熟悉原材料检测的全球药物法规(ICH、NMPA、FDA、EMA、USP、ChP、EP);
- 卓越的沟通和领导能力,能够在跨职能团队中有效工作;
- 具有Microsoft Office、Smartsheet和实验室LIMS及ERP系统(例如SAP)的经验。
Total Views
0
Apply Clicks
0
Weekly mock applicants
0
Bookmarks
0
Similar jobs
About BioNTech

BioNTech
PublicBioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
1,001-5,000
Employees
Mainz that develops immunotherapies
Headquarters
$21.7B
Valuation
Reviews
4.0
10 reviews
Work-life balance
2.5
Compensation
3.8
Culture
4.2
Career
3.5
Management
3.2
75%
Recommend to a friend
Pros
Innovative and cutting-edge projects
Great team and collaborative environment
Excellent benefits and flexible schedule
Cons
Long working hours and high workload
Fast-paced and high-pressure environment
Management and communication issues
Salary Ranges
70 data points
L2
L3
L4
L5
L6
Mid/L4
Intern
L2 · Data Scientist L2
0 reports
$53,767
total per year
Base
$21,507
Stock
$26,884
Bonus
$5,377
$37,637
$69,897
Interview experience
1 interviews
Difficulty
3.0
/ 5
Duration
14-28 weeks
Interview process
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Interview
6
Offer
Common questions
Behavioral/STAR
Technical Knowledge
Past Experience
Culture Fit
Problem Solving
News & Buzz
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily
Oncodaily
News
·
1d ago
BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story - simplywall.st
simplywall.st
News
·
4d ago
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
medwatch.com
News
·
1w ago
BioNTech and DualityBio report positive data for trastuzumab pamirtecan - Clinical Trials Arena
Clinical Trials Arena
News
·
1w ago



